Immunovant Stock Soars 12% After Higher-Dose Arthritis Trial Success And A Narrower Loss
The lower dose failed to outperform placebo, while management plans FDA talks later this year on a path toward approval.
Immunovant, which develops experimental antibody medicines for autoimmune diseases, soared 12.02% to $34.20 in Monday trading as of 9:49 a.m. ET, adding $758 million in market value. The advance followed a narrower quarterly loss and a higher-dose rheumatoid arthritis treatment that met the main goal, according to the company's Monday results release.
Higher Dose Clears The Trial Goal
The arthritis result came with a limitation: the lower dose of IMVT-1402 did not outperform placebo. At week 28, improvement persisted in 92.5% of initial responders who received 600 mg, compared with 75.6% of placebo recipients.
Management used Monday's earnings call to push for an aggressive route toward rheumatoid arthritis approval, but cautioned that the trial design would depend on FDA agreement.
The drug, also known as imeroprubart, is Immunovant's research focus. It targets a protein that keeps antibodies from breaking down; the treatment aims to reduce harmful antibodies that attack a patient's own tissues.
Immunovant's ongoing studies cover six diseases: rheumatoid arthritis that is difficult to treat, Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren's disease and cutaneous lupus. The research reaches across endocrinology, neurology, rheumatology and dermatology, using an injectable formulation administered with an autoinjector.
Research Spending Falls With The Loss
Immunovant's second-quarter loss was $97.2 million, compared with $126.5 million a year earlier. Research costs were $85.0 million, down from $114.2 million.
A Rally Below The Recent Peak
Through Friday's close, Immunovant had gained 20% this year, ahead of the S&P 500's 8% rise. Even with that outperformance, the stock entered Monday 32% below its highest closing price of the past year.
In Monday trading, IMVT shares were on pace for their largest one-day gain since May 20, with the company's market value at about $7.1 billion. The advance came from below the stock's recent peak.
Immunovant plans to discuss the rheumatoid arthritis program's route toward approval with the FDA later this year.
Sources
- North American Morning Briefing: Stock Futures Up But Nvidia Slides Premarket on Huang Probe -2- | Morningstar — morningstar.com
- Immunovant Provides Corporate Updates and Reports Financial — globenewswire.com
- Roivant Reports Financial Results for the Second Quarter — globenewswire.com
- The company's filing (Immunovant) — SEC filing
- Immunovant — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR